ClinicalTrials.gg
RecruitingNCT05848713ATTACC-CAPUpdated Sep 30, 2026

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

A Phase 3 interventional study of Heparin in Community-acquired Pneumonia, sponsored by University of Manitoba. Recruiting at 68 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Manitoba · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Sep 30, 2026First site in MexicoSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Community-Acquired Pneumonia with a site in Brazil — 2 open to participants now, 2 under way, 2 of them phase 3. Community-Acquired Pneumonia · Brazil.

Planned enrollment
Largest of 13
4,000 · median 214
Started
2023
with 2 others
Phase 3
7 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
University of Manitoba

Among the 14 studies in Community-Acquired Pneumonia with a site in Brazil, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 in phase 3, and was the 14th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

2 of the 14 studies in Community-Acquired Pneumonia with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Community-Acquired Pneumonia with a site in Brazil, or all of them as a file.
02

Study summary

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).

Read the detailed description

The global incidence of hospitalization due to CAP is high and associated with substantive morbidity and mortality. Thrombotic complications - including venous, arterial, and possibly microvascular - occur commonly in hospitalized patients across many etiologies of CAP. Poor outcomes may be mediated by both inflammatory and thrombotic processes leading to respiratory, cardiac, and other end organ dysfunction. There are currently no established therapies that modify the potentially maladaptive immunothrombosis pathway in CAP.

Therapeutic-dose anticoagulation with heparin reduces disease progression and mortality in non-critically ill patients hospitalized with COVID-19 with an acceptable safety profile. COVID-19 shares pathogenic features, including activation of the inflammatory and coagulation cascades, with other pneumonias. Whether therapeutic-dose heparin confers similar clinical benefits in non-COVID-19 CAP is unknown.

03

Conditions studied

  • Community-acquired Pneumonia

Keywords

  • Pneumonia
  • Heparin
  • Anticoagulation
  • Community acquired pneumonia
  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Dalteparin
  • Enoxaparin
  • Tinzaparin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age
  2. Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:

    1. Radiographic evidence of new or worsening infiltrate
    2. One or more of the following signs and/or symptoms of lower respiratory tract infection

    i. New or increased cough or sputum production ii. Fever of > 37.8C or temperature \< 36C iii. WBC > 11 x 109/L or \< 4 x 109/L c. The primary diagnosis is believed to be CAP as per the attending physician

  3. Requires supplemental oxygen to treat hypoxemia (or requires an increased level of supplemental oxygen if on chronic oxygen therapy)
  4. Hospital admission anticipated to last ≥72 hours from randomization

Exclusion criteria

Exclusion Criteria:

  1. Suspected or confirmed active COVID-19 infection
  2. Hospital admission for >72 hours prior to randomization
  3. Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
  4. Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
  5. Patients for whom the intent is to not use pharmacologic thromboprophylaxis
  6. Patients with an independent indication for therapeutic-dose anticoagulation
  7. Patients with a to therapeutic-dose anticoagulation, including:

    1. Non-traumatic bleeding that requires medical evaluation or hospitalization within 30 days prior to CAP hospital admission
    2. History of an inherited or acquired bleeding disorder
    3. Cerebral aneurysm or mass lesions of the central nervous system
    4. Ischemic stroke within 3 months of hospital admission
    5. Gastrointestinal bleeding within 3 months of hospital admission
    6. count \<50 x109/L OR >2.0 OR \<80 g/L at the time of screening
    7. Other physician-perceived contraindications to therapeutic anticoagulation
  8. History of heparin induced thrombocytopenia (HIT) or other heparin allergy
  9. Current or recent (within 7 days of screening) use of dual anti-platelet inhibitors (For example; Aspirin + one of the following; clopidogrel, ticagrelor, prasugrel)
  10. Patients in whom imminent death is anticipated
  11. Anticipated transfer to another hospital that is not a study site within 72 hours of randomization
  12. Enrollment in other interventional trials related to anticoagulation or antiplatelet therapy during current hospitalization
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,000 participants (estimated)

Study arms

  • Experimental
    Therapeutic-Dose Heparin

    Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization.

    Drug: Heparin

  • No intervention
    Usual Care

    Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols.

Interventions

  • Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient. Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement.

06

What researchers measure

Primary outcomes

  1. Ordinal endpoint reflecting survival

    Survival to hospital discharge without ICU-level organ support. Organ support is defined as receipt of high flow nasal oxygen, invasive or non-invasive mechanical ventilation, vasopressor/inotropic therapy, or extracorporeal life support (ECLS) within an ICU. This outcome reflects disease progression to ICU-level organ failure or the worst possible outcome (death). It was chosen because of its importance to patients, clinicians, and other stakeholders. Given the limited number of ICU beds, reducing the burden of critical illness has important health system capacity implications.

    Time frame: 30 days

Secondary outcomes

  1. Bleeding events

    Number of participants with major bleeds as defined by the ISTH definition.

    Time frame: 14 days

  2. HIT events

    Number of participants with laboratory confirmed heparin induced thrombocytopenia (HIT)

    Time frame: 14 days

  3. Thrombotic events

    Number of participants with deep vein thrombosis, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke

    Time frame: 30 days and 90 days

  4. Invasive mechanical ventilation

    Ordered categorical endpoint with three possible outcomes based on the worst status of each patient through day 30 following randomization

    Time frame: 30 days

  5. All cause mortality

    Time frame: 30 days, 90 days, and 180 days

  6. Hospital-free days

    Days alive outside hospital

    Time frame: 30 days, 90 days, and 180 days

  7. Health related quality of life

    Using the EQ-5D-5L instrument

    Time frame: 30 days, 90 days, and 180 days

  8. Health related quality of life

    Using the Clinical Frailty Scale instrument

    Time frame: 30 days, 90 days, and 180 days

07

Study locations

53 of 68 sites recruiting
  • University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
    • Jonathan Paul, MD · Contact
  • Ochsner Clinic
    Jefferson, Louisiana 70121, United States
    Recruiting
    • Derek Vondehaar, MD · Contact
  • Maine Medical Centre
    Portland, Maine 04102, United States
    Recruiting
    • Daniel Meyer, MD · Contact
    • Daniel Meyer, MD · Principal investigator
  • Henry Ford Health System
    Dearborn, Michigan 48128, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cooper University Health Care
    Camden, New Jersey 08103, United States
    Recruiting
    • Adam Green, MD · Contact
    • Adam Green, MD · Principal investigator
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Alisha Sharma, MD · Contact
    • Alisha Sharma, MD · Principal investigator
  • Hospital Estadual Dr. Jayme Santos Neves
    Serra, Espírito Santo 29166-828, Brazil
    Recruiting
    • Marcus Matos, MD · Contact
    • Marcus Matos, MD · Principal investigator
  • Hospital Evangelico de Vila Velha
    Vila Velha, Espírito Santo, Brazil
    Recruiting
    • Joao Moraes Junior, MD · Contact
    • Joao Moraes Junior, MD · Principal investigator
    • Guiherme Fonseca, MD · Principal investigator
  • Santa Casa de Misericordia de Itabuna
    Itabuna, Estado de Bahia, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Brasilia
    Brasília, Federal District, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Instituto de Cardiologia e Transplantes do Distrito Federal
    Brasília, Federal District, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Hospital de Messejana Dr. Carlos Alberto Studart Gomes
    Goiânia, Goiás, Brazil
    Recruiting
    • Sandra Nivea dos Reis Saraiva, MD · Contact
    • Sandra Falcao, MD · Principal investigator
  • Hospital Ruy Azeredo
    Goiânia, Goiás, Brazil
    Recruiting
    • Rafael Bastos, MD · Contact
    • Rafael Bastos, MD · Principal investigator
  • Instituto Goiano de Oncologia e Hematologia - INGOH
    Goiânia, Goiás, Brazil
    Recruiting
    • Mayler Santos, MD · Contact
    • Mayler Santos, MD · Principal investigator
  • Hospital São Julião
    Campo Grande, Mato Grosso do Sul, Brazil
    Recruiting
    • Maurício Pompílio Pompílio, MD · Contact
  • Santa Casa de Campo Grande
    Campo Grande, Mato Grosso do Sul, Brazil
    Recruiting
    • Eduardo Calvoso, MD · Contact
  • Hospital Felicio Rocho
    Belo Horizonte, Minas Gerais, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • NUPEC-Orizonti
    Belo Horizonte, Minas Gerais, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Santa Casa de Misericórdia de Belo Horizonte
    Belo Horizonte, Minas Gerais, Brazil
    Recruiting
    • Claudio Dornas, MD · Contact
  • Hospital das Clínicas da Universidade Federal do Triângulo Mineiro
    Uberaba, Minas Gerais, Brazil
    Recruiting
  • Hospital do Rocio
    Campo Largo, Paraná 83606-177, Brazil
    Recruiting
    • CESAR DUSILEK, MD · Contact
  • Hospital Santa Cruz
    Curitiba, Paraná, Brazil
    Recruiting
    • Marcelo Carneiro, MD · Contact
    • Marcelo Carneiro, MD · Principal investigator
  • PUCPR
    Curitiba, Paraná, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Clementino Fraga Filho - UFRJ
    Rio de Janeiro, Rio de Janeiro, Brazil
    Recruiting
    • Fernanda Mello · Contact
  • Hospital Bruno Born
    Lajeado, Rio Grande do Sul, Brazil
    Recruiting
    • Lucas Mallmann, MD · Contact
    • Lucas Mallmann, MD · Principal investigator
  • Hospital Sao Vicente de Paulo
    Passo Fundo, Rio Grande do Sul, Brazil
    Recruiting
    • Alexandre Tognon, MD · Contact
    • Alexandre Tognon · Principal investigator
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting
    • Paulo Dalcin, MD · Contact
    • Paulo Dalcin, MD · Principal investigator
  • Hospital Universitario de Santa Maria
    Santa Maria, Rio Grande do Sul, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Sao Jose
    Criciúma, Santa Catarina, Brazil
    Recruiting
    • Felipe Pizzol, MD · Contact
    • Felipe Pizzol, MD · Principal investigator
  • Hospital Regional Homero Miranda Gomes
    São José, South Carolina, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu
    Botucatu, São Paulo, Brazil
    Recruiting
    • Suzana Erico Tanni, MD · Contact
    • Suzana Erico Tanni, MD · Principal investigator
  • Hospital Universitario Sao Francisco na Providencia na Deus
    Bragança Paulista, São Paulo, Brazil
    Recruiting
    • Gustavo Mamprin, MD · Contact
    • Gustavo Mamprin, MD · Principal investigator
  • Fundação Centro Médico de Campinas
    Campinas, São Paulo 13083-190, Brazil
    Recruiting
    • Otavio Coelho, MD · Contact
    • Otavio Coelho, MD · Principal investigator
  • IPECC
    Campinas, São Paulo, Brazil
    Recruiting
    • Jose Francisco Kerr Saraiva, MD · Contact
    • Jose Francisco Kerr Saraiva, MD · Principal investigator
  • CiTen - Centro Hospital Municipal Antonio Giglio
    Osasco, São Paulo, Brazil
    Recruiting
    • Enrico Fortunato, MD · Contact
    • Enrico Fortunato, MD · Principal investigator
  • Hospital Regional de Presidente Prudente
    Presidente Prudente, São Paulo, Brazil
    Recruiting
    • Luis Felipe Pires, MD · Contact
    • Luis Felipe Pires, MD · Principal investigator
  • Hospital Estadual de Serrana
    Ribeirão Preto, São Paulo, Brazil
    Not yet recruiting
    • Marcos Borges, MD · Contact
    • Marcos Borges, MD · Principal investigator
  • Hospital Nipo-Brasileiro
    São Paulo, São Paulo 02189-010, Brazil
    Recruiting
    • Jose Victor Krasner Schubsky, MD · Contact
  • HCFMUSP
    São Paulo, São Paulo 05403-010, Brazil
    Recruiting
    • Ludhmila Hajjar, MD · Contact
    • Ludhmila Hajjar, MD · Principal investigator
  • Santa Casa de Misericordia de Sao Paulo
    São Paulo, São Paulo, Brazil
    Completed

    Not enrolling at this site — choose another above.

  • Foothills Medical Centre - Alberta Health Services
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
    • Deepa Suryanarayan, MD · Contactdsuryana@ucalgary.ca · 4039448167
    • Deepa Suryanarayan, MD · Principal investigator
  • Grand Prairie Regional Hospital
    Grande Prairie, Alberta T8V 4B1, Canada
    Not yet recruiting
    • Tafi Madzimure, MD · Contact
    • Tafi Madzimure, MD · Principal investigator
  • Nanaimo Regional General Hospital
    Nanaimo, British Columbia, Canada
    Recruiting
    • Alistair Teale, MD · Contact
    • Alistair Teale, MD · Principal investigator
  • Penticton Regional Hospital
    Penticton, British Columbia, Canada
    Not yet recruiting
    • Teresa Rodriguez, MD · Contact
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
    • Ted Steiner, MD · Contact
    • Ted Steiner, MD · Principal investigator
  • Health Sciences Center Winnipeg
    Winnipeg, Manitoba R3A 1R9, Canada
    Recruiting
    • Brett Houstin, MD · Contact
  • Grace General Hospital
    Winnipeg, Manitoba, Canada
    Recruiting
  • St. Boniface General Hospital
    Winnipeg, Manitoba, Canada
    Recruiting
    • Vi Dao, MD · Contact
    • Terry Wuerz, MD · Principal investigator
    • Vi Dao, MD · Principal investigator
  • Memorial University
    St. John's, Newfoundland and Labrador A1C 5S7, Canada
    Recruiting
    • Peter Daley, MD · Contact
    • Peter Daley, MD · Principal investigator
  • Health Sciences North Research Institute
    Greater Sudbury, Ontario P3E 2H3, Canada
    Recruiting
    • Pandma Puranam, MD · Contact
    • Pandma Puranam, MD · Principal investigator
  • Health Sciences North ResearchInstitute (HSNRI)
    Greater Sudbury, Ontario, Canada
    Recruiting
    • Pandma Puranam, MD · Contact
  • Hamilton Health Sciences - Juravinski
    Hamilton, Ontario, Canada
    Recruiting
    • Bram Rochwerg, MD · Contact
    • Bram Rochwerg, MD · Principal investigator
    • Dominik Mertz, MD · Principal investigator
  • Hamilton Health Sciences
    Hamilton, Ontario, Canada
    Recruiting
    • Alison Fox-Robichaud, MD · Contact
    • Alison Fox-Robichaud, MD · Principal investigator
  • Markham Stouffville Hospital
    Markham, Ontario L3P 7P3, Canada
    Recruiting
    • Paul Lee, MD · Contact
    • Paul Lee, MD · Principal investigator
    • Janet Nguyen, MD · Principal investigator
  • Hôpital Montfort
    Ottawa, Ontario, Canada
    Recruiting
    • Marc Carrier, MD · Contact
  • The Ottawa Hospital
    Ottawa, Ontario, Canada
    Recruiting
    • Lana Castellucci, MD · Contact
  • Niagara Health System - St Catharines Site
    Saint Catherines, Ontario L2S 0A9, Canada
    Recruiting
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Jonathan Zipursky, MD · Contact
    • Jonathan Zipursky, MD · Principal investigator
  • St. Michael's Hospital
    Toronto, Ontario, Canada
    Not yet recruiting
    • Michael Colacci, MD · Contact
  • McGill University Health Centre
    Montreal, Quebec H4A3J1, Canada
    Recruiting
    • Emily Gibson McDonald, MD, MSc · Contact
  • Centre Hospitalier de l'université de Montréal (CHUM)
    Montreal, Quebec, Canada
    Recruiting
    • Emmanuelle Duceppe, MD · Contact
  • Jewish General Hospital
    Montreal, Quebec, Canada
    Recruiting
    • Susan Khan, MD · Contact
    • Vicky Tagalakis, MD · Contact
  • CHU de Quebec-University Laval
    Québec, Quebec, Canada
    Recruiting
    • Alexis Turgeon, MD, MSc · Contact
  • Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
    Québec, Quebec, Canada
    Recruiting
    • Francois Lallouche, MD · Contact
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, Quebec, Canada
    Recruiting
    • Francois Lamontagne, MD · Contact
    • Francois Lamontagne, MD · Principal investigator
  • Regina General Hospital
    Regina, Saskatchewan S4P 0W5, Canada
    Recruiting
    • Payam Dehghani, MD · Contact
    • Payam Dehghani, MD · Principal investigator
  • University of Saskatchewan
    Saskatoon, Saskatchewan, Canada
    Not yet recruiting
    • Geroffrey Shumailak, MD · Contact
  • Hospital General Regional 1. Carlos MacGregor Sánchez Navarro
    Mexico City, Mexico City, Mexico
    Recruiting
08

References and documents

Publications

  • ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavik V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, Garcia-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, Lopez-Sendon J, Lopez-Sendon Moreno JL, Lother SA, Malhotra S, Marcos M, Saud Marinez A, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Morillo Guerrero R, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nunez-Garcia B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Perez Gonzalez YS, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Olombrada Santos M, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Shankar-Hari M, Sheehan JP, Singhal AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4. PubMed 34351721 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2028, 53 months after the start.

Of 20 phase 3 interventional studies under Community-Acquired Pneumonia, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 64. This study's planned 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
May 8, 2023
StartActual
Oct 10, 2023
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 7 sites removed — first site in Mexico. 5 sites changed recruiting status (4 now completed, 1 now recruiting)
Show 5 sites
  • University of Chicago · Chicago, United StatesNot yet recruiting→Recruiting
  • Instituto de Cardiologia e Transplantes do Distrito Federal · Brasília, BrazilRecruiting→Completed
  • Hospital Felicio Rocho · Belo Horizonte, BrazilRecruiting→Completed
  • Hospital Universitario de Santa Maria · Santa Maria, BrazilRecruiting→Completed
  • Santa Casa de Misericordia de Sao Paulo · São Paulo, BrazilRecruiting→Completed
Show 11 added (5 Brazil, 5 Canada, 1 Mexico)
  • Hospital São Julião · Campo Grande, Brazil
  • Santa Casa de Campo Grande · Campo Grande, Brazil
  • Santa Casa de Misericórdia de Belo Horizonte · Belo Horizonte, Brazil
  • Hospital das Clínicas da Universidade Federal do Triângulo Mineiro · Uberaba, Brazil
  • Hospital Clementino Fraga Filho - UFRJ · Rio de Janeiro, Brazil
  • Foothills Medical Centre - Alberta Health Services · Calgary, Canada
  • Penticton Regional Hospital · Penticton, Canada
  • Health Sciences North ResearchInstitute (HSNRI) · Greater Sudbury, Canada
  • St. Michael's Hospital · Toronto, Canada
  • University of Saskatchewan · Saskatoon, Canada
  • Hospital General Regional 1. Carlos MacGregor Sánchez Navarro · Mexico City, Mexico
Show 7 removed
  • Hospital Universitário Cassiano Antonio Moraes · Vitória, Brazil
  • Hospital Sao Brasilia · Brasília, Brazil
  • Hospital de Reabilitacao de Anomalias Craniofaciais · Bauru, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo · São Paulo, Brazil
  • Foothills Medical Centre · Calgary, Canada
  • University Health Network · Toronto, Canada
  • Centre Hospitalier de Quebec - Hotel-Dieu de Levis · Lévis, Canada
Sep 30, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Hospital Evangelico de Vila Velha · Vila Velha, BrazilContact added (no phone or email listed)
  • Instituto de Cardiologia e Transplantes do Distrito Federal · Brasília, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Hospital de Messejana Dr. Carlos Alberto Studart Gomes · Goiânia, BrazilContact person changed (no phone or email listed)
  • Hospital Felicio Rocho · Belo Horizonte, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Hospital Universitario de Santa Maria · Santa Maria, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Santa Casa de Misericordia de Sao Paulo · São Paulo, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
Sep 30, 2026
Sponsor
Collaborators added: AVANTI; collaborators removed: Avanti PC
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    11 sites added, 7 sites removed — first site in Mexico. 5 sites changed recruiting status (4 now completed, 1 now recruiting)
    Show 5 sites
    • University of Chicago · Chicago, United StatesNot yet recruiting→Recruiting
    • Instituto de Cardiologia e Transplantes do Distrito Federal · Brasília, BrazilRecruiting→Completed
    • Hospital Felicio Rocho · Belo Horizonte, BrazilRecruiting→Completed
    • Hospital Universitario de Santa Maria · Santa Maria, BrazilRecruiting→Completed
    • Santa Casa de Misericordia de Sao Paulo · São Paulo, BrazilRecruiting→Completed
    Show 11 added (5 Brazil, 5 Canada, 1 Mexico)
    • Hospital São Julião · Campo Grande, Brazil
    • Santa Casa de Campo Grande · Campo Grande, Brazil
    • Santa Casa de Misericórdia de Belo Horizonte · Belo Horizonte, Brazil
    • Hospital das Clínicas da Universidade Federal do Triângulo Mineiro · Uberaba, Brazil
    • Hospital Clementino Fraga Filho - UFRJ · Rio de Janeiro, Brazil
    • Foothills Medical Centre - Alberta Health Services · Calgary, Canada
    • Penticton Regional Hospital · Penticton, Canada
    • Health Sciences North ResearchInstitute (HSNRI) · Greater Sudbury, Canada
    • St. Michael's Hospital · Toronto, Canada
    • University of Saskatchewan · Saskatoon, Canada
    • Hospital General Regional 1. Carlos MacGregor Sánchez Navarro · Mexico City, Mexico
    Show 7 removed
    • Hospital Universitário Cassiano Antonio Moraes · Vitória, Brazil
    • Hospital Sao Brasilia · Brasília, Brazil
    • Hospital de Reabilitacao de Anomalias Craniofaciais · Bauru, Brazil
    • Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo · São Paulo, Brazil
    • Foothills Medical Centre · Calgary, Canada
    • University Health Network · Toronto, Canada
    • Centre Hospitalier de Quebec - Hotel-Dieu de Levis · Lévis, Canada
    Sponsor Collaborators added: AVANTI; collaborators removed: Avanti PC
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Hospital Evangelico de Vila Velha · Vila Velha, BrazilContact added (no phone or email listed)
    • Instituto de Cardiologia e Transplantes do Distrito Federal · Brasília, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Hospital de Messejana Dr. Carlos Alberto Studart Gomes · Goiânia, BrazilContact person changed (no phone or email listed)
    • Hospital Felicio Rocho · Belo Horizonte, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Hospital Universitario de Santa Maria · Santa Maria, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Santa Casa de Misericordia de Sao Paulo · São Paulo, BrazilContact removed (no phone or email listed)Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05848713
Collaborators
Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI, Aurora Clinical Research
Responsible party
Sponsor
First posted
May 8, 2023
Start date
Oct 10, 2023
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Chantale Pineau
Contact
attacc.cap@umanitoba.ca
2042353223
Ryan Zarychanski, MD
principal investigator · University of Manitoba
Patrick Lawler, MD
principal investigator · University Health Network and McGill University
Sylvain Lother, MD
principal investigator · University of Manitoba
Alexis Turgeon, MD
principal investigator · L'Universite Laval

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heparin

Start the discussion